-
Signature
-
/s/ Sarah Dale, Attorney-in-Fact for Amy Weaver
-
Stock symbol
-
CRM
-
Transactions as of
-
Jul 14, 2023
-
Transactions value $
-
-$1,215,932
-
Form type
-
4
-
Date filed
-
7/17/2023, 05:27 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
CRM |
Common Stock |
Options Exercise |
$1.77M |
+11.5K |
+32.74% |
$154.14 |
46.6K |
Jul 14, 2023 |
Direct |
F1 |
transaction |
CRM |
Common Stock |
Options Exercise |
$772K |
+4.78K |
+10.26% |
$161.50 |
51.4K |
Jul 14, 2023 |
Direct |
F1 |
transaction |
CRM |
Common Stock |
Sale |
-$1.22M |
-5.3K |
-10.31% |
$230.34 |
46.1K |
Jul 14, 2023 |
Direct |
F1, F2 |
transaction |
CRM |
Common Stock |
Sale |
-$2.42M |
-10.5K |
-22.73% |
$231.31 |
35.6K |
Jul 14, 2023 |
Direct |
F1, F3 |
transaction |
CRM |
Common Stock |
Sale |
-$116K |
-500 |
-1.4% |
$232.02 |
35.1K |
Jul 14, 2023 |
Direct |
F1, F4 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
CRM |
Non-qualified Stock Option (Right to Buy) |
Options Exercise |
$0 |
-11.5K |
-12.77% |
$0.00 |
78.5K |
Jul 14, 2023 |
Common Stock |
11.5K |
$154.14 |
Direct |
F1, F5 |
transaction |
CRM |
Non-qualified Stock Option (Right to Buy) |
Options Exercise |
$0 |
-4.78K |
-16.67% |
$0.00 |
23.9K |
Jul 14, 2023 |
Common Stock |
4.78K |
$161.50 |
Direct |
F1, F6 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: